O9387
Oxatomide
≥99%
Synonym(s):
1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C27H30N4O
CAS Number:
Molecular Weight:
426.55
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
EC Number:
262-320-9
MDL number:
InChI
1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
InChI key
BAINIUMDFURPJM-UHFFFAOYSA-N
SMILES string
O=C1Nc2ccccc2N1CCCN3CCN(CC3)C(c4ccccc4)c5ccccc5
assay
≥99%
form
powder
color
white
solubility
DMSO: soluble, ethanol: soluble
originator
Johnson & Johnson
Quality Level
Gene Information
human ... DRD3(1814)
Biochem/physiol Actions
Oxatomide is an anti-allergy compound. It suppresses platelet activating factor (PAF)-induced bronchoconstriction and inhibits leukotriene production.
Oxatomide, found in several antihistamines, can suppress mast cell degranulation. It can be used as an alternative to individuals with allergic rhinitis who do not or poorly respond to more established antihistamines. Oxatomide exhibits both antihistamine and anti-inflammatory properties. It exhibits therapeutic effects against asthma and vulvar lichen sclerosus.
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
General description
Oxatomide, a histamine H1-receptor antagonist, is bound at high levels to plasma proteins in human blood.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
D M Richards et al.
Drugs, 27(3), 210-231 (1984-03-01)
Oxatomide is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in
Yong-Soo Park et al.
The Laryngoscope, 116(9), 1642-1646 (2006-09-07)
Inflammatory mediators (IMs) play a major role in the production of middle ear effusion (MEE). Tumor necrosis factor (TNF)-alpha and leukotrienes (LTs) appear to be important in the pathogenesis of otitis media with effusion (OME). The purpose of this study
C Dani et al.
Drugs under experimental and clinical research, 28(5), 207-210 (2003-03-15)
The pharmacokinetics and tolerability of oxatomide oral suspension were investigated in preterm infants to evaluate the feasibility of planning a further study to assess its antiinflammatory effects and its effectiveness in preventing chronic lung disease (CLD). Following the administration of
Drug eruption and liver injury caused by terfenadine and oxatomide.
Takayuki Suyama et al.
European journal of dermatology : EJD, 12(4), 385-386 (2002-07-04)
Gunnar M Buyse et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 11(6), 337-340 (2007-04-27)
The authors report a pilot open-label two-center therapeutic trial of oxatomide in 14 steroid-naive DMD boys aged 5-10 years. Comparison of linear evolutions between 3 months medication-free lead-in periods and 6 months treatment periods showed no significant differences in quantitative
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service